Capital Advisors Ltd’s Terns Pharmaceuticals TERN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-89
| Closed | -$5K | – | 1577 |
|
|
2026
Q1 | $5K | Buy |
89
+84
| +1,680% | +$3.45K | ﹤0.01% | 970 |
|
|
2025
Q4 | $0 | Sell |
5
-84
| -94% | -$1.94K | ﹤0.01% | 1569 |
|
|
2025
Q3 | $1K | Hold |
89
| – | – | ﹤0.01% | 1293 |
|
|
2025
Q2 | $0 | Hold |
89
| – | – | ﹤0.01% | 1621 |
|
|
2025
Q1 | $0 | Sell |
89
-94
| -51% | -$384 | ﹤0.01% | 1574 |
|
|
2024
Q4 | $1K | Hold |
183
| – | – | ﹤0.01% | 1303 |
|
|
2024
Q3 | $2K | Hold |
183
| – | – | ﹤0.01% | 1106 |
|
|
2024
Q2 | $1K | Hold |
183
| – | – | ﹤0.01% | 1296 |
|
|
2024
Q1 | $1K | Hold |
183
| – | – | ﹤0.01% | 1272 |
|
|
2023
Q4 | $1K | Hold |
183
| – | – | ﹤0.01% | 1225 |
|
|
2023
Q3 | $1K | Sell |
183
-5
| -3% | -$32 | ﹤0.01% | 1217 |
|
|
2023
Q2 | $2K | Hold |
188
| – | – | ﹤0.01% | 1049 |
|
|
2023
Q1 | $2K | Hold |
188
| – | – | ﹤0.01% | 940 |
|
|
2022
Q4 | $2K | Sell |
188
-12
| -6% | -$80 | ﹤0.01% | 903 |
|
|
2022
Q3 | $1K | Buy |
200
+98
| +96% | +$364 | ﹤0.01% | 1127 |
|
|
2022
Q2 | $0 | Buy |
+102
| New | +$204 | ﹤0.01% | 1314 |
|
Other funds holding TERN
Capital Advisors Ltd's TERN Position: Q2 2026 in Review
Capital Advisors Ltd sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 89 shares — an estimated $5K sold.
Capital Advisors Ltd first reported a position in TERN in Q2 2022 and held it in 16 quarters. The position peaked at $5K in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.
- Capital Advisors Ltd reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Capital Advisors Ltd sold 89 Terns Pharmaceuticals shares in Q2 2026, an estimated $5K.
- Capital Advisors Ltd first reported a position in Terns Pharmaceuticals in Q2 2022 and held it in 16 quarters.
- Capital Advisors Ltd's Terns Pharmaceuticals position peaked at $5K in Q1 2026.
- 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.
Based on Capital Advisors Ltd's 13F filing for Q2 2026, filed 16 Jul 2026.